Agilon Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Agilon Health, Inc. (NYSE: AGL) on January 7, 2026, reporting an event that occurred on December 31, 2025. The filing discloses the execution of an Amended and Restated Employment Agreement with Jeffrey Schwaneke, the Company's Chief Financial Officer and Executive Vice President, effective January 1, 2026.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements.
Material Changes
The primary material change disclosed is the amendment to Mr. Schwaneke's employment terms, which includes:
- One-Time Equity Award: Grant of 600,000 restricted stock units (RSUs) vesting annually over three years.
- Fiscal Year 2026 Equity: Eligibility for annual equity awards with an aggregate grant-date fair value of $3,750,000, contingent on employment at the time of the general executive grant.
- Fiscal Year 2027 Equity: Eligibility for annual equity awards on terms consistent with other executive officers.
- Severance Provisions: If terminated without cause (and not due to death or disability) within 18 months of January 1, 2026, Mr. Schwaneke is entitled to cash severance equal to 12 months of base salary and target annual bonus, plus continued vesting of equity awards granted under the new agreement.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding the Company's business operations. The only risk or contingency noted is the potential financial obligation for severance and accelerated equity vesting should Mr. Schwaneke's employment be terminated under specific conditions outlined in the agreement.
Key Facts for Investor Verification
- Verify the total number of shares authorized for issuance under the Company's equity incentive plans to assess the impact of the 600,000 RSU grant.
- Review the Company's upcoming periodic reports for the full text of the Amended Employment Agreement.
- Monitor future filings for the actual grant of the $3,750,000 fair value equity award for fiscal year 2026.
- Confirm the Company's current cash position to evaluate the ability to fund potential severance obligations if triggered.